title: Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.
abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.
authors.affiliation: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Lima
authors.forename: Martha
authors.initials: M
authors.lastname: Arellano
authors.forename: Stacie
authors.initials: S
authors.lastname: Holloway
authors.forename: Marian
authors.initials: M
authors.lastname: Shepard
authors.forename: Stephanie
authors.initials: S
authors.lastname: McMillan
authors.forename: Hanna Jean
authors.initials: HJ
authors.lastname: Khoury